Lonza Pharma & Biotech, RPMI Formulations and Raw Material Sourcing: 7 Questions I Get Every Week

Every few weeks, the same questions show up in my inbox from pharma and biotech buyers. I have answered each one so many times that I decided to turn my answers into a checklist you can read in one sitting.

Quick index:

• What Lonza Pharma & Biotech actually does, and how it is different from the media catalog
• Whether an RPMI-1640 formulation from one supplier really differs from another
• What to ask an anionic surfactant supplier before you order
• Why a sulfuric acid production plant cost estimate is rarely the whole story
• Why humans can digest starch but not cellulose—and why excipient buyers should care
• When GMP-grade materials are worth the extra paperwork
• Why quality ends up being a brand decision, not just a purchasing decision

I have made most of the mistakes behind these answers myself. Take what is useful and ignore the rest.

1. Lonza is a CDMO, a chemical company, and a media supplier. Which one am I emailing?

Honestly, all three—and confusing them is one of the most common mistakes I see. Lonza started as a Swiss chemical company back in 1897. Today, the business known as Lonza Pharma & Biotech is mostly a CDMO—a contract development and manufacturing organization that helps pharma and biotech companies produce small molecules, biologics, and cell and gene therapies. The same company also supplies cell culture media, including RPMI-1640, through its bioscience catalog. So you can work with Lonza as a contract manufacturer, as a raw material supplier, or as both.

I learned the hard way in my first year. I routed a question about a media certificate of analysis to the small molecule team because that was the team I trained with. The person asking did not receive a useful answer for almost two days. Not a disaster, but a dumb delay. Now I ask every client the obvious question first: are you buying a service, or are you buying a material? It saves everyone time.

2. Is there a real difference between Lonza RPMI formulation and another supplier's?

I get why people treat RPMI-1640 as a commodity. The medium was developed at Roswell Park Memorial Institute decades ago, and the general composition is public. Every supplier, including Lonza, works from the same basic recipe. A Lonza RPMI formulation lists amino acids, vitamins, inorganic salts—nothing exotic. But here is what I did not understand at first: a recipe is not a process.

Two manufacturers can start with the same formulation and produce different results. Water quality, raw material sourcing, mixing, filtration, packaging, storage, and release testing all affect how the medium actually performs in a bioreactor. I once watched a lab’s cell growth drift after a supplier switch that was based only on an identical ingredients list. The product was not necessarily bad. The problem was that nobody ran a side-by-side comparability study before making the change. Same formulation does not mean same behavior, so test before you switch.

3. What should I ask an anionic surfactant supplier before ordering?

First, stop searching for anionic surfactant as if it were a single product. It is a family: sulfates, sulfonates, carboxylates, phosphates, and more. If you send out a vague inquiry, you will receive quotes for genuinely different chemistries, and you will not be able to compare them.

The mistake I remember most clearly involved sodium lauryl sulfate. I approved an order based on a strong assay number and never asked about the impurity profile. Later we found residual fatty alcohol from the manufacturing route was causing foaming in the customer’s process. I want to say the rework cost was close to $5,200, but I might be misremembering the exact figure. The lesson stuck: purity percentage is not a specification.

Now I ask every supplier the same set of questions:

• What manufacturing route do you use, and what impurities can be present?
• Is the certificate of analysis batch-specific rather than a typical value?
• Will you notify me if the process or the raw material source changes?
• If this is for a pharmaceutical application, do you understand the relevant compendial requirements?

To be fair, a smaller supplier can be excellent and highly responsive. The point is not to reject anyone for size. The point is that a supplier who cannot answer these questions will probably not protect you from surprises later.

4. Why is a sulfuric acid production plant cost estimate always higher than expected?

This question usually comes from someone considering whether to make sulfuric acid rather than buy it. On paper it looks like simple chemistry: burn sulfur to sulfur dioxide, oxidize it to sulfur trioxide, and absorb it into water to make sulfuric acid. It is not the reaction chemistry that makes the budget explode. It is the engineering and compliance around it.

I am not a process engineer, so I cannot give you a credible price per ton. What I can tell you from the procurement side is that every budgetary estimate I have seen left out major pieces: environmental controls for SO2 and acid mist, corrosion-resistant materials, catalyst reloads, heat recovery, waste treatment, utilities, safety systems, and the people who will operate the plant.

In 2022, I sat in on a make-versus-buy review where the first internal estimate looked surprisingly attractive. After the engineering firm added regulatory requirements and environmental controls, the same project no longer looked cheap. I want to say the gap was close to 30%, but I may be misremembering the exact number. The lesson stayed with me: if sulfuric acid production is not your core business, a dedicated plant also carries utilization risk. A plant that runs at 40% capacity is not a low-cost plant.

5. Why can humans digest starch but not cellulose?

Because the bond geometry is different. Starch is made of glucose units connected by alpha-1,4 glycosidic linkages, with some alpha-1,6 branches. Cellulose is also glucose, but linked by beta-1,4 glycosidic bonds. Human amylases fit the alpha linkage like a key in a lock. They cannot split the beta linkage. We do not produce cellulase, so cellulose mostly passes through as dietary fiber instead of becoming digestible glucose.

Why should a pharma or chemical buyer care? Because many excipients are derived from starch or cellulose, and the difference is not just a biology trivia question. Both are polysaccharides of glucose, but their physical behavior in a tablet is completely different: water uptake, swelling, compressibility, disintegration, even compatibility with other ingredients. If someone suggests replacing a cellulose-based excipient with a starch-based one because they are basically the same sugar, be skeptical. The same building blocks can behave very differently depending on how they are linked.

6. Do I really need GMP-grade materials for early research?

For purely exploratory research, research-grade material is probably fine. The problem starts when a team uses research-grade material in a study they later want to cite in a regulatory filing. I made that mistake in 2021, suggesting a cheaper grade to keep a project on budget without checking how the data would be used. The quality unit rejected the study, and we lost about a week. The material was not bad. The documentation was insufficient.

GMP is not only about the product itself. It is about manufacturing being controlled, consistent, and documented. Whether you are buying GMP-grade cell culture media, a compendial-grade surfactant, or an API, you want traceability, change control, batch-specific certificates of analysis, and stability data under defined conditions. For early research, skip it. For clinical or commercial work, do not try to save money at that point in the supply chain.

7. Why not just choose the cheapest supplier? Quality seems like an unnecessary cost.

Let me turn that around: the final product is your brand. If a batch of media fails or a shipment of surfactant is off-spec, you cannot tell your customer that the supplier was cheap. You are the one who approved that supplier. Quality is not a decoration on top of the product. It is part of the first impression your customer gets.

The surfactant mistake I mentioned earlier cost roughly $5,200 in rework and delay. The price difference that led me to that supplier was probably a few hundred dollars. In my experience, quality problems from raw materials flow directly into your own brand. For a pharma or biotech company, the real cost is a failed release, a delayed clinical batch, or lost credibility. That cost is way larger than any ingredient saving.

To be fair, the cheapest option can be an excellent choice if the supplier can demonstrate consistent quality. I am not saying you should always buy premium. I am saying quality should be the filter first, and price should be compared only after that filter is applied. That is what I learned, and that is what I put in our checklist.